The company posted an EBITDA of Rs 74 crore which is 287 per cent increase
Ahmedabad-based Senores Pharmaceuticals has reported revenue of Rs 288 crore during 9MFY25 ending December 31, 2024, reflecting a robust growth of 157 per cent. The exceptional financial performance underscores the company’s strong business strategies and operational excellence.
Key highlights
- Total revenue is Rs 288 crore which is 157 per cent increase
- PAT after MI is Rs 41 crore which is 162 per cent increase
- EBITDA is Rs 74 crore which is 287 per cent increase
- Regulated market business revenues stood at Rs 180.5 crore, a growth of ~100 per cent on a Y-o-Y basis
- Emerging markets business revenues stood at Rs 84.6 crore, growing by more than 10 times on a Y-o-Y basis
Swapnil Shah, MD, Senores Pharmaceuticals said, “We are pleased to report strong performance for Q3 and 9MFY25, driven by our strategy of developing niche products for Regulated Markets and expanding our CDMO/CMO operations. At the same time, we have continued to grow our presence and product portfolio in Emerging Markets. Our revenue and profitability for 9MFY25 have increased by over 150 per cent year-on-year, and we are optimistic about sustaining this momentum going forward.
In Regulated Markets, robust growth in the CDMO/CMO segment was partly offset by softer performance in the Marketed Products segment, which was impacted by the high base of Q3FY24. The consolidation of acquired businesses has resulted in strong growth in the Emerging Markets segment for Q3FY25. Year-on-year, the Regulated Markets and Emerging Markets businesses grew by approximately 100 per cent and over 10 times, respectively, for 9MFY25.
In 9MFY25, the company launched one new product and received ANDA approval for five products in the Regulated Markets business, bringing our total ANDA approvals to 24.
